“What these guidelines highlight … is how far away we’ve moved from ‘one-size-fits-all’ therapy, which usually meant whole brain therapy, to more effective and less toxic therapy personalized to the patient’s symptoms, brain imaging and underlying cancer type,” said Dr. David Schiff, the Harrison Distinguished Teaching Professor of Neurology, Neurological Surgery and Medicine and co-director of the Neuro-Oncology Center at the University of Virginia.